Business Description
Traws Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US68232V3069
Total Employee Number:
7Description
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -0.65 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -119.23 | |||||
Beneish M-Score | 14.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.2 | |||||
3-Year EBITDA Growth Rate | 55.1 | |||||
3-Year EPS without NRI Growth Rate | 53.1 | |||||
3-Year FCF Growth Rate | 49.7 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.43 | |||||
Quick Ratio | 0.43 | |||||
Cash Ratio | 0.24 | |||||
Days Sales Outstanding | 366 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -121.3 | |||||
Shareholder Yield % | -68.55 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -717.82 | |||||
Net Margin % | -710.83 | |||||
EBITDA Margin % | -714.01 | |||||
FCF Margin % | -556.29 | |||||
OCF Margin % | -556.29 | |||||
ROE % | -754.92 | |||||
ROA % | -147.4 | |||||
ROIC % | -764.06 | |||||
3-Year ROIIC % | 77.39 | |||||
ROC (Joel Greenblatt) % | -265108.11 | |||||
ROCE % | -616.65 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.5 | |||||
EV-to-EBIT | -0.39 | |||||
EV-to-EBITDA | -0.39 | |||||
EV-to-Revenue | 2.78 | |||||
EV-to-Forward-Revenue | 1.22 | |||||
EV-to-FCF | -0.5 | |||||
Price-to-GF-Value | 0.05 | |||||
Earnings Yield (Greenblatt) % | -256.41 | |||||
FCF Yield % | -142.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Traws Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2.37 | ||
| EPS (TTM) (€) | -1.466 | ||
| Beta | 0.8644 | ||
| 3-Year Sharpe Ratio | -1.13 | ||
| 3-Year Sortino Ratio | -1.22 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 6.6 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 6.6 - 6.6 | ||
| Shares Outstanding (Mil) | 15.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Traws Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Traws Pharma Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-11-20 09:00 | In 129 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 121 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 08:30 | In 31 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 30 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 6.60 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-04-15 16:30 | 6.60 (+0.00%) | ||
| Annual report for 2025 | 2026-04-15 | 6.60 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-15 | 6.60 (+0.00%) | ||
| General meeting for 2025 | 2025-11-21 09:00 | 6.60 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 6.60 (+0.00%) |
Show
Entries
Traws Pharma Inc Frequently Asked Questions
What is Traws Pharma Inc(FRA:0T20)'s stock price today?
The current price of FRA:0T20 is €6.60. The 52 week high of FRA:0T20 is €6.60 and 52 week low is €6.60.
When is next earnings date of Traws Pharma Inc(FRA:0T20)?
The next earnings date of Traws Pharma Inc(FRA:0T20) is 2026-08-14 Est..
Does Traws Pharma Inc(FRA:0T20) pay dividends? If so, how much?
Traws Pharma Inc(FRA:0T20) does not pay dividend.
Press Release
Articles on Traws Pharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers